Skip to content
Biodatica
Start free

Corbus Pharmaceuticals Inc.

Birmingham, Alabama

OncologyvaccinePhase IIListed · CRBP

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma

3w agoTrial registeredJun 29, 2026Source filing (opens the source filing in a new tab)

Momentum

95no change

Momentum 95 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Sep 29, 2025

    Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma · RECRUITING · sponsor: University of Chicago · Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

    ClinicalTrials.gov · NCT06912087 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Apr 1, 2024

    Solid Tumor, Adult · RECRUITING · sponsor: Corbus Pharmaceuticals Inc. · A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

    ClinicalTrials.gov · NCT06265727 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Mar 7, 2023

    Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat · RECRUITING · sponsor: University of Chicago · Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

    ClinicalTrials.gov · NCT05526924 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Aug 22, 2022

    Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer · ACTIVE_NOT_RECRUITING · sponsor: University of Chicago · TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

    ClinicalTrials.gov · NCT05108870 (opens the source filing in a new tab)

  5. Trial

    Study registered

    Apr 1, 2020

    Cancer, Sars-CoV2 · COMPLETED · sponsor: Imperial College London · COVID-19 and Cancer Patients

    ClinicalTrials.gov · NCT04393974 (opens the source filing in a new tab)

  6. Trial

    PHASE1/PHASE2 registered

    Mar 1, 2019

    Hepatocellular Carcinoma · COMPLETED · sponsor: Imperial College London · Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma

    ClinicalTrials.gov · NCT03682276 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources